News
PASG
10.86
+0.46%
0.05
Weekly Report: what happened at PASG last week (0406-0410)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 4d ago
Passage Bio announces annual shareholder meeting via virtual webcast
Reuters · 04/07 11:01
Weekly Report: what happened at PASG last week (0330-0403)?
Weekly Report · 04/06 09:50
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/01 12:05
Passage Bio Initiated at Outperform by Oppenheimer
Dow Jones · 03/31 14:07
Passage Bio Price Target Announced at $30.00/Share by Oppenheimer
Dow Jones · 03/31 14:07
Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30
Benzinga · 03/31 13:58
PASSAGE BIO INC <PASG.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $30
Reuters · 03/31 12:29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (PASG), Phreesia (PHR) and Esperion (ESPR)
TipRanks · 03/31 08:50
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
Reuters · 03/31 07:39
Passage Bio initiated with an Outperform at Oppenheimer
TipRanks · 03/30 20:14
Weekly Report: what happened at PASG last week (0323-0327)?
Weekly Report · 03/30 09:50
Weekly Report: what happened at PASG last week (0316-0320)?
Weekly Report · 03/23 09:48
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 03/19 12:06
Weekly Report: what happened at PASG last week (0309-0313)?
Weekly Report · 03/16 09:47
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway
TipRanks · 03/10 11:55
Weekly Report: what happened at PASG last week (0302-0306)?
Weekly Report · 03/09 09:49
Passage Bio Price Target Cut to $23.00/Share From $67.00 by Canaccord Genuity
Dow Jones · 03/04 19:11
Passage Bio Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/04 19:11
More
Webull provides a variety of real-time PASG stock news. You can receive the latest news about Passage Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.